Table 1 Brief characteristics of included studies
First author | Year | Journal | Study stage | No. of patientsa | PD-1/PD-L1 inhibitors | Dose | Combination drug | Male (%) | Median age | dMMR-MSI-H rate (%) | Median follow-up time |
|---|---|---|---|---|---|---|---|---|---|---|---|
M. J. Overman | 2017 | Lancet Oncol | II | 74 | Nivolumab | 3 mg/kg iv q2w | None | 44 (59) | 52.5 | 100 % | 12m |
B. H. O'Neil | 2017 | PLoS One | Ib | 23 | Pembrolizumab | 10mg/kg iv q2w | None | 13 (57) | 57 | 4 % | 5.3m |
M. D. Hellmann | 2019 | Ann Oncol | Ib | 84 | Atezolizumab | 800 mg iv q2w | Cobimetinib | N/A | N/A | 2.30 % | 17m |
D. T. Le | 2019 | J Clin Oncol | II | 124 | Pembrolizumab | 200 mg q3w | None | 69 (56) | 56 | 100 % | 31.3m/24.2m b |
T. André | 2020 | N Engl J Med | III | 153 | Pembrolizumab | 200mg q3w | None | 71 (46) | 63 | 100 % | 32.4m |
D.T. Le | 2015 | N Engl J Med | II | 28 | Pembrolizumab | 10mg/kg iv q2w | None | N/A | N/A | 36 % | 9m/5m b |
M. J. Overman | 2018 | J Clin Oncol | II | 119 | Nivolumab | 3mg/kg iv q3w/q2w | Ipilimumab | 70 (59) | 58 | 100 % | 13.4m |
E. X. Chen | 2020 | JAMA Oncol | II | 119 | Durvalumab | 1500mg iv q4w | Tremelimumab | 74 (62) | 65 | <2 % | 15.2m |
R. Cohen | 2020 | J Immunother Cancer | II | 57 | Nivolumab | 3mg/kg iv q3w/q2w | Ipilimumab | 30 (53) | 56.5 | 100 % | 12m |
C. Wangc | 2020 | Oncologist | - | 18 | Nivolumab/ pembrolizumab | N:240mg iv q2w, P:200mg iv q3w | Regorafenib | 16 (89) | 60 | 0 % | 7m |
S. Fukuoka | 2020 | J Clin Oncol | Ib | 25 | Nivolumab | 3mg/kg q2w | Regorafenib | 18 (72) | 55 | 4 % | N/A |
J. Lic | 2020 | Front Oncol | - | 23 | Different kinds of inhibitors | & | Regorafenib | 16 (70) | 50 | 0 % | 7.9m |
C. Ren | 2020 | Am J Cancer Res | II | 9 | Shr-1210 | 200mg iv q2w | Apatinib | N/A | 54 | 0 % | N/A |
C. Eng | 2019 | Lancet Oncol | III | 273 | Atezolizumab | 840mg iv q2w/ 1200mg iv q3w | Cobimetinib or none | 166 (61) | 56 | 2.20 % | 7.3m |